A case of lung cancer resistant to pemetrexed responding to S-1 monotherapy

Japanese Journal of Cancer and Chemotherapy

Volumn 40, Issue 6, 2013, Pages 781-784

  Oyamada, Yoshitaka ^a   Maeshima, Arafumi ^a   Takeuchi, Ken ^a   Kato, Ryoichi ^a  

^a NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

Author keywords

Lung cancer; PEM; S 1

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUOROURIDINE MONOPHOSPHATE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; PEMETREXED; PHOSPHATE; RNA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CASE REPORT; HUMAN; LUNG CANCER; MALE; TREATMENT RESPONSE;

EID: 84882798962     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Shih C, Chen VJ, Gossett LS, et al: LY231514, a pyrrolo [2,3-d] pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57(6):1116-1123, 1997. (Pubitemid 27138611)
2. Selvaggi G and Scagliotti GV: Histologic subtype in NSCLC: does it matter? Oncology (Williston Park) 23 (13): 1133-1140, 2009.
3. Pizzorno G, Moroson BA, Cashmore AR, et al: Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM. Cancer Res 55(3):566-573, 1995.
4. Rhee MS, Ryan TJ and Galivan J: Glutamyl hydrolase and the multitargeted antifolate LY 231514. Cancer Chemother Pharmacol 44(5):427-432, 1999. (Pubitemid 29455590)